

Pictet - Biotech - HR AUS / LU2353392348 / A3CS8K / Pictet AM (EU)

Last 10/02/2024 ¹	Region	Branch	Type of yield	Type
780.05 AUD	Worldwide	Sector Biotechnology	reinvestment	Equity Fund



Risk key figures

SRI: 1 2 3 4 5 6 7

Mountain-View Funds Rating²: EDA³

73

Yearly Performance

Master data		Conditions		Other figures	
Fund type	Single fund	Issue surcharge	3.00%	Minimum investment	UNT 0
Category	Equity	Planned administr. fee	0.00%	Savings plan	-
Sub category	Sector Biotechnology	Deposit fees	0.05%	UCITS / OGAW	Yes
Fund domicile	Luxembourg	Redemption charge	1.00%	Performance fee	0.00%
Tranch volume	(10/02/2024) USD 0.398 mill.	Ongoing charges	-	Redeployment fee	0.00%
Total volume	(10/02/2024) USD 1,593.51 mill.	Dividends		Investment company	
Launch date	6/22/2021	Pictet AM (EU)			
KEST report funds	Yes	6B, rue du Fort Niedergruenewald, 2226, Luxembourg			
Business year start	01.10.	Luxembourg			
Sustainability type	Ethics/ecology	www.am.pictet/de/germany			
Fund manager	Tazio Storni, Lydia Haueter, Marco Minonne, Eugénio Martin-Fougeroux				

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	-6.74%	+4.49%	+4.03%	+23.74%	-	-	-	+22.07%
Performance p.a.	-	-	-	+23.67%	-	-	-	+14.04%
Sharpe ratio	-3.09	0.26	0.10	0.85	-	-	-	0.50
Volatility	19.96%	22.34%	22.12%	23.97%	0.00%	0.00%	0.00%	21.70%
Worst month	-	-8.05%	-8.05%	-11.72%	-11.72%	0.00%	0.00%	-11.72%
Best month	-	6.53%	18.28%	18.28%	18.28%	0.00%	0.00%	18.28%
Maximum loss	-6.74%	-10.08%	-15.56%	-15.56%	0.00%	0.00%	0.00%	-

Distribution permission

Austria, Germany, Switzerland, Luxembourg, Czech Republic

¹ Important note on update status: The displayed date refers exclusively to the calculation of the NAV.

² The Mountain-View Data Fund Rating calculates a comparative ranking for funds using yield, volatility and trend data. For more information visit [MVD Funds Rating](#)

DISCLAIMER: The information on this page are for informational purposes only and should neither an offer to sell nor a solicitation for the purchase of the security or recommendation in favor of the security to be understood. baha GmbH assumes no liability despite thorough searches for the accuracy of the data.

Funds data from: www.mountain-view.com. Fact Sheet created by: www.baha.com

Pictet - Biotech - HR AUS / LU2353392348 / A3CS8K / Pictet AM (EU)

Investment strategy


In actively managing the Compartment, the investment manager uses a combination of market and fundamental company analysis to select securities that it believes offer favourable growth prospects at a reasonable price. The investment manager considers ESG factors a core element of its strategy by seeking to invest mainly in economic activities that contribute to a social objective whilst avoiding activities that adversely affect society or the environment. Voting rights are methodically exercised and there may be engagement with companies to positively influence ESG practices. For further information, please refer to our exclusion framework in the Responsible Investment policy*, SFDR product category Article 9. The portfolio composition is not constrained relative to the benchmark, so the similarity of the Compartment's performance to that of the benchmark may vary.

Investment goal


To increase the value of your investment while seeking to achieve a positive social impact. Reference Index MSCI AC World (USD), an index that does not take into account environmental, social and governance (ESG) factors. Used for risk monitoring, performance objective and performance measurement. Portfolio Assets The Compartment mainly invests in equities of companies operating in the medical biotechnology sector. The Compartment may invest worldwide, including in emerging markets and Mainland China, although most of investments are concentrated in the United States of America and Western Europe.

Assessment Structure


Assets



Largest positions



Countries



Branches

